Insider Selling: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Sells $362,246.40 in Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Kevin Joseph Fitzgerald sold 1,440 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total value of $362,246.40. Following the transaction, the executive vice president now owns 12,881 shares of the company’s stock, valued at $3,240,344.36. The trade was a 10.06 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Kevin Joseph Fitzgerald also recently made the following trade(s):

• On Friday, February 14th, Kevin Joseph Fitzgerald sold 663 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $255.21, for a total value of $169,204.23.

Alnylam Pharmaceuticals Trading Up 0.8 %

Shares of NASDAQ:ALNY opened at $252.49 on Friday. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $304.39. The business’s fifty day simple moving average is $254.04 and its 200-day simple moving average is $263.12. The company has a market capitalization of $32.69 billion, a PE ratio of -116.36 and a beta of 0.35. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). As a group, equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.94 earnings per share for the current fiscal year.

Analyst Ratings Changes

ALNY has been the topic of a number of research analyst reports. Piper Sandler reaffirmed an “overweight” rating and set a $296.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday, November 18th. HC Wainwright reissued a “buy” rating and set a $400.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday, January 13th. Barclays raised their price objective on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an “overweight” rating in a research note on Friday, November 1st. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Tuesday, February 11th. Finally, StockNews.com lowered Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, January 9th. One analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $299.48.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Allworth Financial LP increased its holdings in shares of Alnylam Pharmaceuticals by 6.8% in the 4th quarter. Allworth Financial LP now owns 597 shares of the biopharmaceutical company’s stock valued at $140,000 after acquiring an additional 38 shares during the period. Investment Management Corp of Ontario boosted its position in shares of Alnylam Pharmaceuticals by 0.6% in the 4th quarter. Investment Management Corp of Ontario now owns 7,099 shares of the biopharmaceutical company’s stock worth $1,670,000 after purchasing an additional 40 shares in the last quarter. Nixon Peabody Trust Co. boosted its position in shares of Alnylam Pharmaceuticals by 1.9% in the 4th quarter. Nixon Peabody Trust Co. now owns 2,293 shares of the biopharmaceutical company’s stock worth $540,000 after purchasing an additional 43 shares in the last quarter. Brevan Howard Capital Management LP boosted its position in shares of Alnylam Pharmaceuticals by 3.4% in the 4th quarter. Brevan Howard Capital Management LP now owns 1,333 shares of the biopharmaceutical company’s stock worth $314,000 after purchasing an additional 44 shares in the last quarter. Finally, Huntington National Bank boosted its position in shares of Alnylam Pharmaceuticals by 91.8% in the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 45 shares in the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.